Clinical trial • Psychiatry

MELATONIN for Psychiatric disorder | Insomnia

Clinical trial of MELATONIN for Psychiatric disorder | Insomnia.

Overview

Trial Therapeutic Area
Psychiatry
Trial Disease
Psychiatric disorder | Insomnia
Drug Modality
Small molecule | Small molecule | Other
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
03-01-2025
First CTIS Authorization Date
14-04-2025

Trial design

Randomised, melatonin (melatonin orifarm 3 mg film-coated tablets; product strength 3 mg, max daily dose listed as 9 mg) versus low-dose quetiapine (quetiapin sandoz 25 mg film-coated tablets; product strength 25 mg, max daily dose listed as 150 mg) versus placebo (starch and lactose containing gelatine capsules). specific dosing schedules/frequency in-protocol not specified in ctis summary.-controlled trial across 1 site in Denmark.

Randomised
Yes
Comparator
Melatonin (Melatonin Orifarm 3 mg film-coated tablets; product strength 3 mg, max daily dose listed as 9 mg) versus low-dose quetiapine (Quetiapin Sandoz 25 mg film-coated tablets; product strength 25 mg, max daily dose listed as 150 mg) versus placebo (Starch and Lactose containing gelatine capsules). Specific dosing schedules/frequency in-protocol not specified in CTIS summary.
Target Sample Size
255

Eligibility

Recruits 255 paediatric patients.

Pregnancy Exclusion
Women of childbearing potential: negative pregnancy test at baseline and use of highly effective contraception measures
Vulnerable Population
Includes adolescents (16-17 years). Informed consent must be provided by both the minor and the legally designated representative (consent/assent handling specified). The CTIS record lists subject information and consent documents for parents and youths (e.g. L1_Flles samtykkeerklring til forldre og unge; L2_Forldrefuldmagt; L1_SIS_unge; L1_SIS_forldre). The trial population is not flagged as 'vulnerable' in the CTIS population selection (isVulnerablePopulationSelected: false).

Inclusion criteria

  • {"criterion_text":"- 16 to 17 years of age\n- ICD-10 diagnosis of a current or previous mental or behavioral disorder (F20-F69, F84, F90-F95)\n- For the diagnoses F84 and F90 a previous period of treatment with melatonin is required\n- Self-reported sleep difficulties at least three times per week in the preceding 3 months\n- Insomnia Severity Index score ≥11\n- Non-pharmacological treatment options including sleep hygiene education, weighted blanket or other gravity products have been tested with insufficient effect\n- Women of childbearing potential: negative pregnancy test at baseline and use of highly effective contraception measures\n- Informed consent provided by both the minor and the legally designated representative"}

Exclusion criteria

  • {"criterion_text":"- Current treatment with melatonin or quetiapine\n- Severe somatic comorbidity\n- BMI ≥ 35 kg/m2\n- Breastfeeding\n- Alcohol and/or substance dependency (F1X.2) within the last 3 months\n- Inadequate Danish language skills\n- Not able to make an informed consent\n- Increased cardiac risk as assessed by presence of cardiac risk factors, cardiac symptoms, or prolonged QT-interval at baseline electrocardiogram (ECG)"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Insomnia severity using the Insomnia Severity Index (ISI)","definition_or_measurement_approach":"Measured using the Insomnia Severity Index (ISI)."}

Secondary endpoints

  • {"endpoint_text":"- Clinical global impression (CGI)","definition_or_measurement_approach":"Measured using the Clinical Global Impression (CGI) scale."}
  • {"endpoint_text":"- Subjective sleep quality using the Pittsburgh Sleep Quality Index (PSQI)","definition_or_measurement_approach":"Measured using the Pittsburgh Sleep Quality Index (PSQI)."}
  • {"endpoint_text":"- Psychosocial functioning using the Personal and Social Performance Scale (PSP)","definition_or_measurement_approach":"Measured using the Personal and Social Performance Scale (PSP)."}
  • {"endpoint_text":"- Patient-reported subjective well-being using the WHO-5 well-being index","definition_or_measurement_approach":"Measured using the WHO-5 well-being index."}
  • {"endpoint_text":"- Rest-sleep-activity cycles and physiological variables","definition_or_measurement_approach":"Rest-sleep-activity cycles and physiological variables (measurement approach not specified in CTIS record)."}

Recruitment

Registry Or Advocacy Recruitment
True: forskningNU | forsoegstjenestenDK | forsoegspersonDK
Digital Remote Recruitment
True: online announcements/advertisements on research volunteer portals (forskningNU, forsoegstjenestenDK, forsoegspersonDK) as indicated by recruitment material titles.
Planned Sample Size
255
Recruitment Window Months
49
Consent Approach
Informed consent must be provided by both the minor and the legally designated representative. CTIS lists subject information and consent forms for parents and youths (examples: L1_Flles samtykkeerklring til forldre og unge; L1_SIS_unge; L1_SIS_forldre; L2_Forldrefuldmagt). An adult consent form ('L1_ICF_Samtykkeerklring voksne') is also present in documents.

Methods

  • Plakat A3 (recruitment poster) — indicated by document title 'K2_ Recruitment material_Plakat A3' (channel: poster; target audience: adolescents and parents in Denmark).
  • Online advertisement to research volunteer portals — indicated by document title 'K2_Recruitment material_Annonce til forskningNU forsoegstjenestenDK og forsoegspersonDK' (channels: online research volunteer portals; target audience: adolescents/parents in Denmark).
  • Leaflet A5 — indicated by document title 'K2_ Recruitment material_Pjece A5' (channel: leaflet/brochure; target audience: adolescents and parents in Denmark).
  • Recruitment arrangements document 'K1_ Recruitment arrangements' (procedural recruitment arrangements; country: Denmark).

Geography

Total Number Of Sites
1
Total Number Of Participants
255

Denmark

Earliest CTIS Part Ii Submission Date
21-03-2025
Latest Decision Or Authorization Date
14-04-2025
Processing Time Days
24
Number Of Sites
1
Number Of Participants
255

Sites

Site Name
Psykiatrisk Center Kobenhavn
Department Name
Bispebjerg
Principal Investigator Name
Lone Baandrup
Principal Investigator Email
Lone.Baandrup@regionh.dk
Contact Person Name
Lone Baandrup
Contact Person Email
Lone.Baandrup@regionh.dk
Number Of Participants
255

Sponsor

Primary sponsor

Full Name
Psykiatrisk Center Kobenhavn
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"sponsorDuties code 1","organisation_type":"Hospital/Clinic/Other health care facility"}

Investigational products

Investigational Product Name
Melatonin Orifarm 3 mg filmdragerade tabletter
Active Substance
MELATONIN
Modality
Small molecule
Routes Of Administration
Oral
Route
Oral
Authorisation Status
Marketing authorisation information present (prodAuthStatus: 2; euMpNumber PRD11434328; authorisation country: SE)
Maximum Dose
9 mg daily
Investigational Product Name
Quetiapin Sandoz 25 mg filmdrasjerte tabletter
Active Substance
QUETIAPINE
Modality
Small molecule
Routes Of Administration
Oral
Route
Oral
Authorisation Status
Marketing authorisation information present (prodAuthStatus: 2; euMpNumber PRD2233998; authorisation country: NO)
Maximum Dose
150 mg daily
Investigational Product Name
Starch and Lactose containing gelatine capsules
Modality
Other

Related trials

Other published trials that may interest you.